Rucaparib and Nivolumab in Treating Patients with Advanced or Metastatic Biliary Tract Cancer after Platinum Therapy
Multiple Cancer Types
This phase II trial studies how well rucaparib and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body after platinum therapy. Rucaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and nivolumab after platinum therapy may help kill more cancer cells that are left after chemotherapy.